Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2006-05-30
2006-05-30
Badio, Barbara P. (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S172000, C540S048000, C540S049000, C540S052000
Reexamination Certificate
active
07053076
ABSTRACT:
Disclosed are compounds that exhibit high transport across the intestinal wall of an animal. The compounds may optionally be linked to drugs that are poorly absorbed or poorly transported across the intestinal wall after oral administration to provide for enhanced therapeutic, and optionally prolonged therapeutic, systemic blood concentrations of the drugs upon oral administration of the drug-compound conjugate. Also disclosed are pharmaceutical compositions containing and methods of using such compounds.
REFERENCES:
patent: 4848349 (1989-07-01), Sherman et al.
patent: 4866044 (1989-09-01), Sato et al.
patent: 5462933 (1995-10-01), Kramer et al.
patent: 5646272 (1997-07-01), Kramer et al.
patent: 5668126 (1997-09-01), Kramer et al.
patent: 0 285 285 (1988-10-01), None
patent: 0 624 593 (1994-11-01), None
patent: 0 676 410 (1995-10-01), None
patent: 0 702 026 (1997-06-01), None
patent: 10-286453 (1998-10-01), None
patent: 11-60594 (1999-03-01), None
patent: WO 90/13298 (1990-11-01), None
patent: WO 94/00126 (1994-01-01), None
patent: WO 95/03056 (1995-02-01), None
patent: WO 97/18816 (1997-05-01), None
patent: WO 97/44043 (1997-11-01), None
patent: WO 98/01159 (1998-01-01), None
patent: WO 99/15179 (1999-04-01), None
patent: WO 99/52932 (1999-10-01), None
patent: WO 00/20437 (2000-04-01), None
patent: WO 00/34461 (2000-06-01), None
patent: WO 00/38738 (2000-07-01), None
patent: WO 00/40965 (2000-07-01), None
patent: WO 00/57915 (2000-10-01), None
patent: WO 00/66611 (2000-11-01), None
Baringhaus, et al., “Substrate Specificity of the Ileal and the Hepatic Na+/bile acid Cotransporters of the Rabbit. II.A Relaible 3D QSAR Pharmacophore Model for the Ileal Na+/bile acid Cotransporter”,J. of Lipid Res., vol. 40, pp. 2158-2168 (1999).
Begum, et al., “Synthesis of 2β-Hydroxyursolic Acid and Other Ursane Analogues from Ursonic Acid”,Aust. J. Chem, vol. 46, pp. 1067-1071 (1993).
Bellini, et al., “Studi su 5beta-chetosteroidi—Nota VII. Derivati pirimidinici e pteridinici dell'acido 3,7,12-trichetocolanico”,Il Farmaco—Ed. Sc., vol. 25, fax. 3, pp. 226-233.
Bellini, et al., “Studi su 5β-cheto-steroidi.—Nota IV. Derivati eterociclici sugi anelli A e B dell'acido 3,7,12-tricheto-colanico”,Gazetta Chimica Italiana, vol. 99, fasc. XII, pp. 1243-1251 (1969).
Brouwer, et al., “An Efficient Synthesis of N-Protected β-Aminoethansulfonyl Chlorides”,Synthesis, No. 11, pp. 1579-1584 (2000).
Clinton, et al., “Steroidal[3,2-c]pyrazoles. II. Androstanes, 19-Norandrostanes and their Unsaturated Analogs”,J. of American Chem. Soc., vol. 83, pp. 1478-1491 (1961).
Ho, et al., “Utilizing Bile Acid Carrier Mechanisms to Enahnce Liver and Small Intestine Absorption”,Ann. New York Acad. Sci., pp. 315-329 (1987).
Junjappa, H., et al., “α-Oxoketene-S,S-, N,S- And N,N-Acetals: Versatile Intermediates in Organic Synthesis”,Tetrahedron Report, No. 278, pp. 5423-5506 (1990).
Kim, et al., “Evaluation of Bile Acid Transporter in Enhancing Intestinal Permeaility of Renin-Inhibitory Peptides”,J. Drug TargetingI, vol. 1, pp. 347-359 (1993).
Kramer, et al., “Substrate Specificity of the Ileal and the Hepatic Na+/Bile Acid Cotransporters of the Rabbit. I. Transport Studies with Membrane Vesicles and Cell Lines Expressing the Cloned Transporters”,J. of Lipid Res., vol. 40, pp. 1604-1617 (1999).
Kramer, et al., “Liver-Specific Drug Targeting by Coupling to Bile Acids”,J. Biol. chem., vol. 267, pp. 18598-18604 (1992).
Kramer, et al., “Intestinal Absporption of Peptides by Coupling to Bile Acids”,J. of Biol. Chem., vol. 269, No. 14, pp. 10621-10627 (1994).
Kramer, et al., “Bile Acid Derived HMG-CoA Reductase Inhibitors”,Biochim. Biophys. Acta, vol. 1227, pp. 137-154 (1994).
Kullak-Ublick, et al., “Hepatobiliary Transport”,J. Hepatology, vol. 32, pp. 3-18 (2000).
Navia, et al., “Design Principles for Orally Bioavailable Drugs”,Drug Discovery Today, vol. 1, pp. 179-189 (1996).
Paquette, L.A., et al., “2-Chloro-1-Formyl-1-Cyclohexene”,Organic Syntheses, vol. 5, pp. 215-232.
Petzinger, E., et al., “Hepatobiliary Transport of Hepatic 3-hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Conjugated with Bile Acids”,Hepatology, vol. 22, pp. 1801-1811 (1995).
Rocchi, R., et al., “Studi Su 5β-Cheto-Steroidi, Nota VI—Derivati Pirimidinici e pteridinici degli acidi 3,12-dicheto—e 7,12-dichetocolanici”,Il Farmaco. Ed. Sc., vol. 25, Fasc. 2, pp. 125-132 (1970).
Spivey, et al., “A New Germanium-Based Linker for Solid Phase Synthesis of Aromatics: Synthesis of a Pyrazole Library”,J. Org. Chem., vol. 65, pp. 5253-5263 (2000).
Swaan, P.W., et al., “Use of the Intestinal and Hepatic bile Acid Transporters for Drug Delivery”,Adv. Drug Delivery Rev., vol. 20, pp. 59-82 (1996).
Tserng, “A Convenient Synthesis of 3-Keto Bile Acids by Selective Oxidation of Bile Acids with Silver Carbonate-Celite”,J. of Lipid Res., vol. 19, pp. 501-504 (1978).
Tsuji, et al. “Carrier-Mediated Intestinal Transport of Drugs”,Pharmaceutical Res., vol. 13, No. 7, pp. 963-977 (1996).
Venepalli, B., et al., “Synthesis and Substance P Receptor Binding Activity of Androstano[3,2-b]pyrimido[1,2-a]benzimidazoles”,J. Med. Chem, vol. 35, pp. 374-378 (1992).
Bhat Laxminarayan
Gallop Mark A.
Jandeleit Bernd
Badio Barbara P.
Buchanan & Ingersoll PC
XenoPort, Inc.
LandOfFree
Bile-acid derived compounds for enhancing oral absorption... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bile-acid derived compounds for enhancing oral absorption..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bile-acid derived compounds for enhancing oral absorption... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3627593